Chi-Med, Lilly to jointly commercialize colorectal cancer therapy in China
Hutchison China MediTech announced it has expanded its role in commercializing fruquintinib, the cancer therapy the company co-developed with and licensed to Eli Lilly for the China market.
Originally discovered by Chi-Med, the Hong Kong-listed drug developer partnered with Lilly in 2013 to develop the cancer therapy as a potential treatment for various types of solid tumors. China’s National Medical Products Administration approved the drug in 2018 for the treatment of metastatic colorectal cancer, which is now marketed as Elunate.
Starting in October, Chi-Med will take charge of the development and execution of all on-the-ground marketing activities in China for Elunate, while Lilly to continue to collaborate with the Chinese pharma in the drug’s marketing strategy. The U.S. drug maker also maintains the exclusive commercialization rights for the drug and will consolidate its sales in China.
“Lilly has concluded that Chi-Med is actually very well-placed to be used by Lilly to execute all commercial on-the-ground marketing activities and medical detailing,” Chi-Med CEO Christian Hogg told STAT.
The company is in the process of building out its commercial team in China to market Elunate, and for the anticipated launch of its neuroendocrine tumor therapy surufatinib later this year.
“We're heavily motivated and incentivized to push fruquintinib as hard as possible, and that’s our total single-minded focus at the moment — to maximize the potential of fruquintinib in China,” Hogg said.
Two Phase 3 studies for Elunate are ongoing — the FRUTIGA study for the second-line treatment of gastric cancer in China, and the FRESCO-2 global registration study for treating metastatic colorectal cancer.
Originally discovered by Chi-Med, the Hong Kong-listed drug developer partnered with Lilly in 2013 to develop the cancer therapy as a potential treatment for various types of solid tumors. China’s National Medical Products Administration approved the drug in 2018 for the treatment of metastatic colorectal cancer, which is now marketed as Elunate.
Starting in October, Chi-Med will take charge of the development and execution of all on-the-ground marketing activities in China for Elunate, while Lilly to continue to collaborate with the Chinese pharma in the drug’s marketing strategy. The U.S. drug maker also maintains the exclusive commercialization rights for the drug and will consolidate its sales in China.
“Lilly has concluded that Chi-Med is actually very well-placed to be used by Lilly to execute all commercial on-the-ground marketing activities and medical detailing,” Chi-Med CEO Christian Hogg told STAT.
The company is in the process of building out its commercial team in China to market Elunate, and for the anticipated launch of its neuroendocrine tumor therapy surufatinib later this year.
“We're heavily motivated and incentivized to push fruquintinib as hard as possible, and that’s our total single-minded focus at the moment — to maximize the potential of fruquintinib in China,” Hogg said.
Two Phase 3 studies for Elunate are ongoing — the FRUTIGA study for the second-line treatment of gastric cancer in China, and the FRESCO-2 global registration study for treating metastatic colorectal cancer.
.png)
No hay comentarios:
Publicar un comentario